| Advanced or Metastatic Solid Tumors or Neoplasms |
CA191-002,
NCT00569036 |
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors |
Recruiting |
Details |
| Cancer |
CA165-017,
NCT00326131 |
A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer |
Terminated |
Details |
| Cancer |
CA180-003,
NCT00099606 |
Phase I (PH I) Mad Refractory Solid Tumor Study |
Completed |
Details |
| Cancer |
CA194-002,
NCT00670189 |
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer |
Recruiting |
Details |
| Cancer |
CA198-001,
NCT00838890 |
A Study of BMS-863233 in Patients With Hematologic Cancer |
Terminated |
Details |
| Cancer |
MDX1105-01,
NCT00729664 |
Study of MDX-1105 in Subjects With Selected Advanced or Recurrent Solid Tumors |
Recruiting |
Details |
| Cancer |
MDX1106-02,
NCT00703469 |
A Study of MDX-1106 to Treat Patients With Hepatitis C Infection |
Completed |
Details |
| Cancer |
MDX1106-03,
NCT00730639 |
A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies |
Recruiting |
Details |
| Cancer |
MDX1203-01,
NCT00944905 |
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) |
Recruiting |
Details |
| Cancer, Adenocarcinomas |
CA225-063,
NCT00162110 |
A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces |
Completed |
Details |
| Cancer, Advanced |
CA124-002,
NCT00057473 |
A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors |
Completed |
Details |
| Cancer, Advanced |
CA124-003,
NCT00990912 |
A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002) |
Completed |
Details |
| Cancer, Advanced |
CA163-085,
NCT00162136 |
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies. |
Completed |
Details |
| Cancer, Advanced |
CA163-088,
NCT00309049 |
Ixabepilone Administered as an Enteric Coated Formulation. |
Completed |
Details |
| Cancer, Advanced |
CA163-111,
NCT00422097 |
A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer |
Active, not recruiting |
Details |
| Cancer, Advanced |
CA163-149,
NCT00632424 |
Phase 1 Trial of Oral Ixabepilone |
Terminated |
Details |
| Cancer, Advanced |
CA163-196,
NCT00883116 |
A Study of Ixabepilone as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer |
Recruiting |
Details |
| Cancer, Advanced |
CA165-021,
NCT00103831 |
Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer |
Completed |
Details |
| Cancer, Advanced |
CA180-004,
NCT00452673 |
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer |
Active, not recruiting |
Details |
| Cancer, Advanced |
CA180-011,
NCT00324077 |
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase |
Withdrawn |
Details |
| Cancer, Advanced |
CA180-274,
NCT00948389 |
Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM) |
Recruiting |
Details |
| Cancer, Advanced |
CA181-002,
NCT00095537 |
BMS-599626 in Patients With Advanced Solid Malignancies |
Completed |
Details |
| Cancer, Advanced |
CA181-003,
NCT00207012 |
MAD Refractory: Solid Tumor QD w/o Break |
Completed |
Details |
| Cancer, Advanced |
CA182-002,
NCT00207103 |
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors |
Completed |
Details |
| Cancer, Advanced |
CA182-007,
NCT00300027 |
Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies |
Terminated |
Details |
| Cancer, Advanced |
CA182-022,
NCT00437437 |
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664) |
Active, not recruiting |
Details |
| Cancer, Advanced |
CA182-026,
NCT00633789 |
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types |
Recruiting |
Details |
| Cancer, Advanced |
CA182-030,
NCT00798252 |
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers |
Recruiting |
Details |
| Cancer, Advanced |
CA182-033,
NCT00858871 |
First Line Hepato Cellular Carcinoma (HCC) |
Recruiting |
Details |
| Cancer, Advanced |
CA182-047,
NCT01108705 |
Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Asian Subjects Who Have Failed Sorafenib Treatment |
Recruiting |
Details |
| Cancer, Advanced |
CA183-001,
NCT00101608 |
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium |
Completed |
Details |
| Cancer, Advanced |
CA183-002,
NCT00389155 |
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy |
Completed |
Details |
| Cancer, Advanced |
CA183-008,
NCT00362830 |
A Study of the Alternative Administration of Ixabepilone and Vinflunine |
Completed |
Details |
| Cancer, Advanced |
CA183-009,
NCT00388557 |
Effect of Ketoconazole on the Pharmacokinetics of Vinflunine |
Completed |
Details |
| Cancer, Advanced |
CA183-033,
NCT00534807 |
A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer |
Withdrawn |
Details |
| Cancer, Advanced |
CA185-002,
NCT00326586 |
A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer |
Completed |
Details |
| Cancer, Advanced |
CA187-002,
NCT00329004 |
A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors |
Completed |
Details |
| Cancer, Advanced |
CA187-006,
NCT00516451 |
Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors |
Completed |
Details |
| Cancer, Advanced |
CA187-020,
NCT01167244 |
Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response |
Not yet recruiting |
Details |
| Cancer, Advanced |
CA190-001,
NCT00546247 |
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1) |
Terminated |
Details |
| Cancer, Advanced |
CA190-002,
NCT00550017 |
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2) |
Terminated |
Details |
| Cancer, Advanced |
CA191-003,
NCT00898716 |
Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan |
Recruiting |
Details |
| Cancer, Advanced |
CA191-004,
NCT00788333 |
Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer |
Recruiting |
Details |
| Cancer, Advanced |
CA191-005,
NCT00793897 |
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors |
Recruiting |
Details |
| Cancer, Advanced |
CA191-006,
NCT00908024 |
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors |
Recruiting |
Details |
| Cancer, Advanced |
CA194-003,
NCT00884546 |
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma |
Recruiting |
Details |
| Cancer, Advanced |
CA198-002,
NCT00886782 |
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors |
Terminated |
Details |
| Cancer, Advanced |
CA205-001,
NCT01018745 |
Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan |
Completed |
Details |
| Cancer, Advanced |
CA209-004,
NCT01024231 |
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma |
Recruiting |
Details |
| Cancer, Advanced |
CA225-085,
NCT00110357 |
Study of Erbitux" (Cetuximab) in Pediatric Patients With Refractory Solid Tumors |
Completed |
Details |
| Cancer, Advanced |
CA225-315,
NCT00698841 |
Study to Evaluate the Effect of Cetuximab on Corrected QT Interval Changes in Patients With Advanced Malignancies From Solid Tumors |
Completed |
Details |
| Cancer, Advanced |
L0070 IN 302 P1,
NCT00315237 |
Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract |
Completed |
Details |
| Cancer, Advanced |
MDX1411-01,
NCT00656734 |
Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer. |
Active, not recruiting |
Details |
| Cancer, Bladder |
CA184-027,
NCT00362713 |
Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection |
Completed |
Details |
| Cancer, Breast |
CA139-371,
NCT01023204 |
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer |
Completed |
Details |
| Cancer, Breast |
CA139-387,
NCT00971945 |
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer |
Completed |
Details |
| Cancer, Breast |
CA161-006,
NCT00036621 |
A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy |
Terminated |
Details |
| Cancer, Breast |
CA163-046,
NCT00080301 |
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer |
Completed |
Details |
| Cancer, Breast |
CA163-048,
NCT00082433 |
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer |
Completed |
Details |
| Cancer, Breast |
CA163-081,
NCT00080262 |
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC) |
Completed |
Details |
| Cancer, Breast |
CA163-100,
NCT00455533 |
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer |
Completed |
Details |
| Cancer, Breast |
CA163-102,
NCT00207090 |
Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer |
Completed |
Details |
| Cancer, Breast |
CA163-104,
NCT00322374 |
Phase I Combination w/ Epirubicin |
Completed |
Details |
| Cancer, Breast |
CA163-107,
NCT01019577 |
Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant |
Completed |
Details |
| Cancer, Breast |
CA163-115,
NCT00370552 |
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer |
Completed |
Details |
| Cancer, Breast |
CA163-117,
NCT00568022 |
A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer |
Completed |
Details |
| Cancer, Breast |
CA163-130,
NCT01027208 |
A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline |
Completed |
Details |
| Cancer, Breast |
CA163-131,
NCT00546364 |
This is a Study of Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer |
Terminated |
Details |
| Cancer, Breast |
CA163-144,
NCT00634088 |
Phase I Study of Ixabepilone + Lapatinib +/- Capecitabine to Treat HER2 Positive Locally Advanced or Metastatic Breast Cancer |
Terminated |
Details |
| Cancer, Breast |
CA180-059,
NCT00371254 |
A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer |
Completed |
Details |
| Cancer, Breast |
CA180-088,
NCT00371345 |
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer |
Completed |
Details |
| Cancer, Breast |
CA180-158,
NCT00754325 |
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor |
Recruiting |
Details |
| Cancer, Breast |
CA180-185,
NCT00696072 |
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic |
Recruiting |
Details |
| Cancer, Breast |
CA180-261,
NCT00767520 |
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer |
Recruiting |
Details |
| Cancer, Breast |
CA185-005,
NCT00644488 |
A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer |
Completed |
Details |
| Cancer, Breast |
CA187-016,
NCT01068704 |
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer |
Recruiting |
Details |
| Cancer, Breast |
CA200-001,
NCT00773344 |
Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin |
Completed |
Details |
| Cancer, Breast |
CA201-001,
NCT00803556 |
Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy |
Completed |
Details |
| Cancer, Breast |
CA201-002,
NCT00780000 |
Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer |
Terminated |
Details |
| Cancer, Breast |
MDX010-12,
NCT00083278 |
Study of MDX-010 in Stage IV Breast Cancer |
Completed |
Details |
| Cancer, Breast, Early-Stage |
CA163-139,
NCT00633464 |
Randomized Phase II of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer |
Active, not recruiting |
Details |
| Cancer, Breast, Early-Stage |
CA163-140,
NCT00490646 |
A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer |
Active, not recruiting |
Details |
| Cancer, Colorectal |
CA182-025,
NCT00594984 |
Phase I/II Combination With Irinotecan- Erbitux |
Recruiting |
Details |
| Cancer, Colorectal |
CA196-004,
NCT00851045 |
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer |
Recruiting |
Details |
| Cancer, Colorectal |
CA206-001,
NCT01086267 |
Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer |
Recruiting |
Details |
| Cancer, Colorectal |
CA225-045,
NCT00207155 |
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer |
Completed |
Details |
| Cancer, Colorectal |
CA225-259,
NCT00362102 |
A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma |
Completed |
Details |
| Cancer, Esophageal |
CA139-540,
NCT00344552 |
Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer |
Completed |
Details |
| Cancer, Esophageal |
CA139-557,
NCT00971841 |
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer |
Active, not recruiting |
Details |
| Cancer, Esophageal |
CA194-004,
NCT00909402 |
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas |
Recruiting |
Details |
| Cancer, Gastrointestinal |
CA163-200,
NCT00983801 |
Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer |
Recruiting |
Details |
| Cancer, Gastrointestinal |
CA182-003,
NCT00207051 |
BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies |
Completed |
Details |
| Cancer, Gastrointestinal |
CA182-034,
NCT00825955 |
Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment |
Recruiting |
Details |
| Cancer, Gastrointestinal |
CA182-037,
NCT00908752 |
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC |
Recruiting |
Details |
| Cancer, Gastrointestinal |
CA182-046,
NCT01046864 |
Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) |
Recruiting |
Details |
| Cancer, Head and Neck |
CA139-372,
NCT01024101 |
Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer |
Completed |
Details |
| Cancer, Head and Neck |
CA139-384,
NCT00337532 |
A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer |
Completed |
Details |
| Cancer, Head and Neck |
CA139-388,
NCT00855764 |
Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer |
Completed |
Details |
| Cancer, Head and Neck |
CA139-539,
NCT00971867 |
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer |
Completed |
Details |
| Cancer, Head and Neck |
CA184-042,
NCT00623766 |
Study of Ipilimumab to Treat Melanoma in Patients With Brain Metastases |
Active, not recruiting |
Details |
| Cancer, Head and Neck |
CA186-005,
NCT00461110 |
A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC) |
Terminated |
Details |
| Cancer, Hepatocellular |
CA182-006,
NCT00355238 |
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer |
Active, not recruiting |
Details |
| Cancer, Hepatocellular |
CA182-015,
NCT00437424 |
A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction |
Active, not recruiting |
Details |
| Cancer, Lung |
CA184-041,
NCT00527735 |
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) |
Active, not recruiting |
Details |
| Cancer, Melanoma |
CA184-004,
NCT00261365 |
Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010) |
Completed |
Details |
| Cancer, Melanoma |
CA184-007,
NCT00135408 |
A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide |
Completed |
Details |
| Cancer, Melanoma |
CA184-008,
NCT00289627 |
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma |
Completed |
Details |
| Cancer, Melanoma |
CA184-022,
NCT00289640 |
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma |
Completed |
Details |
| Cancer, Melanoma |
CA184-024,
NCT00324155 |
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma |
Active, not recruiting |
Details |
| Cancer, Melanoma |
CA184-025,
NCT00162123 |
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies |
Active, not recruiting |
Details |
| Cancer, Melanoma |
CA184-029,
NCT00636168 |
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma |
Recruiting |
Details |
| Cancer, Melanoma |
CA184-045,
NCT00495066 |
Compassionate Use Trial for Unresectable Melanoma With Ipilimumab |
Available |
Details |
| Cancer, Melanoma |
CA184-087,
NCT00920907 |
Comparison of Ipilimumab Manufactured by Two Different Processes in Patients With Advanced Melanoma |
Active, not recruiting |
Details |
| Cancer, Melanoma |
CA186-001,
NCT00309023 |
Study of BMS-663513 in Patients With Advanced Cancer |
Terminated |
Details |
| Cancer, Melanoma |
CA186-006,
NCT00612664 |
Phase II, 2nd Line Melanoma - RAND Monotherapy |
Completed |
Details |
| Cancer, Melanoma |
CA186-007,
NCT00803374 |
Combination of Anti-CD137& Ipilimumab in Patients With Melanoma |
Withdrawn |
Details |
| Cancer, Melanoma |
CDR0000365467,
NCT00084656 |
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma |
Completed |
Details |
| Cancer, Melanoma |
MDX010-08,
NCT00050102 |
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma |
Completed |
Details |
| Cancer, Melanoma |
MDX010-15,
NCT00729950 |
Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma |
Completed |
Details |
| Cancer, Melanoma |
MDX010-20,
NCT00094653 |
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Melanoma |
Completed |
Details |
| Cancer, Metastatic |
CA183-023,
NCT00359476 |
A Study of Vinflunine in Patients With Gastric Cancer |
Terminated |
Details |
| Cancer, Metastatic Breast |
CA163-132,
NCT00593827 |
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer (MBC) |
Active, not recruiting |
Details |
| Cancer, Myeloma |
CA180-180,
NCT00560391 |
Dasatinib in Combination With Revlimid (and Dexamethasone) |
Active, not recruiting |
Details |
| Cancer, Myeloma |
CA180-181,
NCT00560352 |
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma |
Active, not recruiting |
Details |
| Cancer, Myeloma |
CA200-003,
NCT00514371 |
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma |
Completed |
Details |
| Cancer, Myeloma |
CA200-004,
NCT00546780 |
A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse |
Suspended |
Details |
| Cancer, Non-Small-Cell Lung |
BMS TAX/MEN.12,
NCT00035152 |
Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer |
Completed |
Details |
| Cancer, Non-Small-Cell Lung |
CA139-373,
NCT01024062 |
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Details |
| Cancer, Non-Small-Cell Lung |
CA163-011,
NCT00035516 |
A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy |
Completed |
Details |
| Cancer, Non-Small-Cell Lung |
CA163-160,
NCT00683904 |
Ixabepilone in Combination With Carboplatin in Patients With Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Details |
| Cancer, Non-Small-Cell Lung |
CA163-163,
NCT00723957 |
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer |
Active, not recruiting |
Details |
| Cancer, Non-Small-Cell Lung |
CA163-177,
NCT00832117 |
Phase I Combination Ixabepilone + Cisplatin |
Recruiting |
Details |
| Cancer, Non-Small-Cell Lung |
CA165-020,
NCT00099879 |
Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer |
Terminated |
Details |
| Cancer, Non-Small-Cell Lung |
CA165-026,
NCT00359450 |
Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer) |
Terminated |
Details |
| Cancer, Non-Small-Cell Lung |
CA165-030,
NCT00332748 |
A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer |
Terminated |
Details |
| Cancer, Non-Small-Cell Lung |
CA184-078,
NCT00796991 |
DDI - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine |
Active, not recruiting |
Details |
| Cancer, Non-Small-Cell Lung |
CA184-113,
NCT01165216 |
Japanese Study of Ipilimumab in Combination With Paclitaxel/Carboplatin |
Not yet recruiting |
Details |
| Cancer, Non-Small-Cell Lung |
CA187-017,
NCT00743938 |
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC |
Recruiting |
Details |
| Cancer, Non-Small-Cell Lung |
CA196-005,
NCT00850577 |
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer |
Recruiting |
Details |
| Cancer, Non-Small-Cell Lung |
CA202-002,
NCT00651508 |
Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Details |
| Cancer, Non-Small-Cell Lung |
CA225-064,
NCT00162318 |
A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer |
Completed |
Details |
| Cancer, Non-Small-Cell Lung |
CA225-065,
NCT00207116 |
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma |
Completed |
Details |
| Cancer, Non-Small-Cell Lung |
CA225-099,
NCT00112294 |
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer |
Completed |
Details |
| Cancer, Non-Small-Cell Lung |
CA225-100,
NCT00112346 |
Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer |
Completed |
Details |
| Cancer, Non-Small-Cell Lung |
CA225-101,
NCT00207077 |
Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors |
Completed |
Details |
| Cancer, Non-Small-Cell Lung |
CA225-322,
NCT00768131 |
A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel |
Withdrawn |
Details |
| Cancer, Non-Small-Cell Lung |
CA225-346,
NCT01109524 |
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer |
Recruiting |
Details |
| Cancer, Ovarian |
CA186-004,
NCT00351325 |
A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies |
Terminated |
Details |
| Cancer, Pancreatic Cancer |
CA163-116,
NCT00383149 |
A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer |
Completed |
Details |
| Cancer, Prostate |
CA180-085,
NCT00385580 |
Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer |
Active, not recruiting |
Details |
| Cancer, Prostate |
CA180-086,
NCT00439270 |
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer |
Active, not recruiting |
Details |
| Cancer, Prostate |
CA180-227,
NCT00744497 |
Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer |
Recruiting |
Details |
| Cancer, Prostate |
CA184-043,
NCT00861614 |
Study of Immunotherapy to Treat Advanced Prostate Cancer |
Recruiting |
Details |
| Cancer, Prostate |
CA184-095,
NCT01057810 |
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer |
Recruiting |
Details |
| Cancer, Prostate |
CA192-002,
NCT00605618 |
Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors |
Completed |
Details |
| Cancer, Prostate |
MDX010-07,
NCT00050596 |
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer |
Completed |
Details |
| Cancer, Prostate |
MDX010-21,
NCT00323882 |
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer |
Completed |
Details |
| Cancer, Small-Cell Lung |
CA194-005,
NCT00927875 |
A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer |
Recruiting |
Details |
| Cancer, Solid Tumors |
CA163-029,
NCT01018966 |
Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors |
Completed |
Details |
| Cancer, Solid Tumors |
CA180-058,
NCT00339144 |
Study of Dasatinib(BMS-354825) in Patients With Solid Tumors |
Completed |
Details |
| Cancer, Solid Tumors |
CA187-003,
NCT00578916 |
Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects |
Completed |
Details |
| Cancer, Solid Tumors |
CA187-004,
NCT00420186 |
A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin |
Recruiting |
Details |
| Cancer, Solid Tumors |
CA187-005,
NCT00479583 |
Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX |
Recruiting |
Details |
| Cancer, Solid Tumors |
CA195-001,
NCT00792558 |
Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers |
Withdrawn |
Details |
| Cancer, Solid Tumors |
CA196-007,
NCT01146171 |
Japanese Phase 1 Study of BMS-844203 (CT322) |
Not yet recruiting |
Details |
| Cancer, Solid Tumors |
CA200-002,
NCT00779428 |
Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin |
Enrolling by invitation |
Details |
| Cancer, Solid Tumors, Advanced |
CA165-012,
NCT00207025 |
A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies |
Terminated |
Details |
| Clinical Pharmacology |
CA163-038,
NCT00207129 |
Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies |
Completed |
Details |
| Leukemia |
CA180-002,
NCT00103701 |
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia |
Completed |
Details |
| Leukemia |
CA180-005,
NCT00101647 |
Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia |
Completed |
Details |
| Leukemia |
CA180-006,
NCT00101816 |
Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate |
Completed |
Details |
| Leukemia |
CA180-013,
NCT00101660 |
Study of BMS-354825 in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib |
Completed |
Details |
| Leukemia |
CA180-015,
NCT00101595 |
Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
Completed |
Details |
| Leukemia |
CA180-017,
NCT00103844 |
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia |
Completed |
Details |
| Leukemia |
CA180-021,
NCT00162214 |
Study of Dasatinib in Patients With Advanced Solid Tumors |
Terminated |
Details |
| Leukemia |
CA180-031,
NCT00337454 |
Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan |
Completed |
Details |
| Leukemia |
CA180-033,
NCT00298987 |
A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate |
Completed |
Details |
| Leukemia |
CA180-034,
NCT00123474 |
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML |
Active, not recruiting |
Details |
| Leukemia |
CA180-035,
NCT00123487 |
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML |
Active, not recruiting |
Details |
| Leukemia |
CA180-036,
NCT01030718 |
Rollover Study of BMS-354825 in Patients With CML and Ph+ALL |
Completed |
Details |
| Leukemia |
CA180-039,
NCT00978731 |
Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study |
Completed |
Details |
| Leukemia |
CA180-043,
NCT00320190 |
Study of Dasatinib in Patients With Chronic Phase CML and a Suboptimal Response to Imatinib |
Completed |
Details |
| Leukemia |
CA180-056,
NCT00481247 |
A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML |
Active, not recruiting |
Details |
| Leukemia |
CA180-083,
NCT00349518 |
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL |
Withdrawn |
Details |
| Leukemia |
CA180-109,
NCT00454753 |
Korean Early Access Program |
Approved for marketing |
Details |
| Leukemia |
CA180-138,
NCT00482703 |
A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia |
Completed |
Details |
| Leukemia |
CA180-160,
NCT00529763 |
Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Accelerated Phase) Subjects |
Active, not recruiting |
Details |
| Leukemia |
CA180-182,
NCT00872976 |
Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia |
Withdrawn |
Details |
| Leukemia |
CA180-188,
NCT00982488 |
START Rollover Study |
Active, not recruiting |
Details |
| Leukemia |
CA180-249,
NCT00655746 |
The Effect of Omeprazole on the Pharmacokinetics of Dasatinib in Healthy Subjects |
Completed |
Details |
| Leukemia |
CA184-033,
NCT00732186 |
Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia |
Withdrawn |
Details |
| Leukemia |
CA212-001,
NCT01120457 |
First in Human Study to Determine the Safety, Tolerability and Preliminary Effectiveness of MDX-1338 (BMS 936564) in Subjects With Acute Myelogenous Leukemia (AML) |
Not yet recruiting |
Details |
| Leukemia, Chronic Myeloid (CML) |
CA180-044,
NCT00362466 |
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy |
Terminated |
Details |
| Leukemia, Pediatric |
CA180-018,
NCT00306202 |
Study of BMS-354825 in Children and Adolescents With Relapsed or Refractory Leukemia |
Active, not recruiting |
Details |
| Leukemia, Pediatric |
CA180-226,
NCT00777036 |
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib |
Recruiting |
Details |
| Liver Desease, Chronic |
CA180-051,
NCT00382668 |
A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug |
Completed |
Details |
| Lymphoma |
MDX1401-01,
NCT00634452 |
Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma |
Active, not recruiting |
Details |
| Scleroderma |
CA180-267,
NCT00764309 |
Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis |
Active, not recruiting |
Details |
| Solid tumors |
CA182-008,
NCT00435669 |
A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664) |
Completed |
Details |
| Solid tumors |
CA182-012,
NCT00390936 |
A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors |
Completed |
Details |